CSDE1 Knockout GIST-T1 Cell Line

Product Type:
Genome-edited Cells
Tissue Source:
Gastrointestinal (GI) tract
Disease:
Stromal tumor
Host Cell:
GIST-T1
Gene Name:
CSDE1
Inquire Now
✓ In stock
🚚 Ships next business day
Ask a Question

The CSDE1 Knockout GIST-T1 Cell Line is a CRISPR/Cas9-edited knockout cell line from the GIST-T1 cell line, a human gastrointestinal stromal tumor model with a KIT exon 11 deletion. It disrupts the CSDE1 RNA-binding protein, which modulates targets including c-FOS and PTEN mRNAs and interacts with UPF1 and PABP, linking it to MAPK/ERK and PI3K/AKT pathways. This knockout cell line is ideal for investigating post-transcriptional regulation in cancer, assessing proliferation and apoptosis, and performing assays such as Western blotting, RT-qPCR, RIP, and dual-luciferase reporter assays. It supports studies on GIST tumor biology, drug screening, and RNA regulatory mechanisms.

Shipping Info: Cryopreserved in vials and shipped on dry ice

Disclaimer: For Research Use Only
Host CellGIST-T1
MorphologyEpithelial-like
Age47 years
Sex of DonorFemale
Gene NameCSDE1
Gene IdentifierNCBI Gene ID 7812
Temperature37°C
Atmosphere5% CO₂
Sterility testingDaily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.
Mycoplasma testingNegative for mycoplasma through PCR analysis
PathogensCells tested negative for HIV-1, HBV, and HCV.

Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.

This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.

Description

The CSDE1 Knockout GIST-T1 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the GIST-T1 human gastrointestinal stromal tumor (GIST) cell line. It features a loss-of-function mutation in the CSDE1 gene, generated via CRISPR/Cas9-mediated gene disruption. This model enables functional studies of the CSDE1 RNA-binding protein in a KIT-mutant, tumorigenic mesenchymal background, providing a platform to investigate post-transcriptional regulatory mechanisms in cancer.

GIST-T1 is an established cell line from a human GIST harboring an activating KIT exon 11 deletion (V560_Y578del), driving constitutive MAPK/ERK and PI3K/AKT signaling. Widely used in GIST research, these cells recapitulate the oncogenic properties of the disease and serve as a relevant host for examining the impact of CSDE1 knockout on KIT-dependent pathways.

CSDE1 (UNR) is an RNA-binding protein that interacts with PABP, UPF1, eIF4G, and PAIP1 to regulate mRNA stability and translation. It acts as a translational repressor or activator and participates in nonsense-mediated mRNA decay and IRES-mediated translation. CSDE1 is regulated by AKT phosphorylation and the MAPK/ERK pathway, with miR-125b modulating its expression. It controls key targets including c-FOS, c-JUN, PTEN, and BCL2 mRNAs, linking it to cell proliferation, apoptosis, and cell cycle progression.

In GIST-T1 cells, where KIT mutation aberrantly activates downstream signaling, CSDE1 knockout may disrupt post-transcriptional control of oncogenes and tumor suppressors. Altered expression of targets such as c-FOS and PTEN can impact MAPK/ERK and PI3K/AKT network output, influencing proliferation and survival. This model thus allows dissection of how RNA-binding protein function intersects with kinase-driven oncogenesis in GIST.

This cell line is suitable for target validation by Western blotting and RT-qPCR, protein?CRNA interaction studies via RIP, IRES activity analysis using dual-luciferase reporters, and functional assays including MTT/BrdU proliferation and annexin V apoptosis measurements. It also supports co-immunoprecipitation with UPF1 and PABP, and RNA-seq transcriptome profiling. These applications address roles of CSDE1 in GIST tumorigenesis, post-transcriptional regulation, and drug target screening. For additional information, contact Ascent Research.